Key result
Novel single-component TMV stent demonstrates proper pulsatile-flow function and 24 Fr delivery system compatibility.
Why the study?
Elderly patients frequently suffer from secondary mitral regurgitation but are often ineligible for surgical valve replacement due to high procedural risks.
A novel single-component, dual-diameter transcatheter mitral valve stent demonstrated feasibility and proper function in in vitro pulsatile-flow testing.
Answers are grounded in this paper and cite their sources.
Does not support clinical use; leaves open in vivo durability and human translation for this mitral valve design.
Background: The development of transcatheter mitral valves (TMVs) represents a major advancement in cardiology, driven in part by the growing elderly population. These patients frequently suffer from secondary mitral regurgitation but are often ineligible for surgical valve replacement due to high procedural risks. This study aimed to develop a self-expanding TMV stent fabricated from a single nitinol tube, featuring two distinct central zones: a smaller-diameter valve-containing segment and a larger-diameter anchoring segment for the mitral annulus. Methods: Biotechnical engineering using COMSOL Multiphysics software package, manufacturing prototypes of stents and valves in 5 sizes, 22 Fr delivery system compatibility assessment, and pulsatile-flow testing. Results: We bioengineered a novel stent design with an integrated porcine pericardial valve. The stents were laser-cut from nitinol tubes (4.5 mm outer diameter, 0.45 mm wall thickness) and heat-treated to achieve spatial configurations compatible with fibrous ring diameters of 40, 42, 44, 46, and 48 mm. Pericardial leaflets and coverings were then mounted onto the stents. The resulting valves were successfully loaded into a 24 Fr delivery system and exhibited proper opening and closing function under pulsatile-flow testing. Conclusions: Our findings confirm the feasibility of a single-component, dual-diameter TMV stent, offering a promising solution for high-risk patients with mitral regurgitation.
No takes yet. Share an insight, caveat, or question.
I.Yu. Zhuravleva (2025) studied Mitral regurgitation. Self-expanding transcatheter mitral valve (TMV) stent with dual annulus/valve diameter was evaluated on Delivery system compatibility and pulsatile-flow testing. A novel single-component, dual-diameter transcatheter mitral valve stent was successfully bioengineered, loaded into a 24 Fr delivery system, and exhibited proper function in pulsatile-flow testing.
Synapse has enriched 10 related papers. Consider them for comparative context: